Biology of Reproduction · 2003 · 270 citations · 23 references
Life SciencesGeneticsMolecular BiologyChromatin BiologyChromatin StructureEpigeneticsChromatinEpigenetic Regulation In DevelopmentEpigenetic ReprogrammingHistone ModificationsHistone ProteinsReproductive EpigeneticsChromatin OrganizationCloned Embryo DevelopmentEmbryo EpigeneticsEpigenetic Regulation In BlastocystsHistone AcetylationHistone DeacetylationHistone MethylationNuclear Transfer Cloning
Blastocyst formation after nuclear transfer relies on donor cell genome reprogramming, a process that is inefficient and influenced by chromatin organization. The study aimed to enhance donor cell reprogrammability by treating them with the histone deacetylase inhibitor trichostatin A and the DNA methyltransferase inhibitor 5‑aza‑2′‑deoxycytidine. Treatment with 1.25 or 5 µM TSA elevated histone H3 acetylation, 0.3 µM 5‑aza‑dC reduced DNA methylation, and both drugs at 0.08 µM induced morphological changes in donor fibroblasts. Blastocyst development was reduced by 0.08 or 0.3 µM 5‑aza‑dC (9.7 % and 4.2 %) but increased by 0.08 µM TSA (35.1 % vs 25.1 %), indicating that partial erasure of epigenetic marks improves cloned embryo development.
Development to blastocyst following nuclear transfer is dependent on the donor cell's ability to reprogram its genome to that of a zygote. This reprogramming step is inefficient and may be dependent on a number of factors, including chromatin organization. Trichostatin A (TSA; 0–5 μM), a histone deacetylase inhibitor, was used to increase histone acetylation and 5-aza-2′-deoxycytidine (5-aza-dC; 0–5 μM), a DNA methyl-transferase inhibitor, was used to decrease methylation of chromatin in donor cells in an attempt to improve their reprogrammability. Adult fibroblast cells treated with 1.25 or 5 μM TSA had elevated histone H3 acetylation compared to untreated controls. Cells treated with 0.3 μM 5-aza-dC had decreased methylation compared to untreated controls. Both drugs at 0.08 μM caused morphological changes of the donor cells. Development to blastocysts by embryos cloned from donor cells after 0.08 or 0.3 μM 5-aza-dC treatments was lower than in embryos cloned from untreated control cells (9.7% and 4.2%, respectively, vs. 25.1%), whereas 0.08 μM TSA treatment of donor cells increased blastocyst development compared to controls (35.1% vs. 25.1%). These results indicate that partial erasure of preexisting epigenetic marks of donor cells improves subsequent in vitro development of cloned embryos.
23
Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription
Peter Lloyd Jones, Gert Jan C. Veenstra, Paul A. Wade et al. · Nature Genetics · 1998 · 2.7K citations
Cellular differentiation, cytidine analogs and DNA methylation
Peter A. Jones, Shirley M. Taylor · Cell · 1980 · 1.9K citations
Demethylation of the zygotic paternal genome
Wolfgang Mayer, Alain Niveleau, Jörn Walter et al. · Nature · 2000 · 1.3K citations